Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Jasper Therapeutics (NASDAQ:JSPR) and maintained a $6 price target.
October 12, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Jasper Therapeutics and maintained a $6 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Jasper Therapeutics. The maintained price target of $6 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100